Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma

Yuanyuan Gu1, Jing Meng2, Yongzhi Ju3, Xia You3, Tingting Sun3, Jun Lu4 and Yin Guan1*

1Department of Medical Oncology, Beijing Chao–Yang Hospital, Capital Medical University, Beijing, China, 2Department of Medical Oncology, The Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China, 3The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China, 4Department of Pathology, Beijing Chao–Yang Hospital, Capital Medical University, Beijing, China

Angiosarcoma (AS) is a rare, clinically aggressive tumor with limited treatment options and a poor prognosis. Mutations involving the angiogenesis-related genes TP53, PTPRB, PLCG1, KDR as well as FLT4 amplification have been observed in AS. There is a potential therapeutic value of inhibition of the VEGF pathway against angiosarcoma. Our case first described a patient with two sites of cutaneous angiosarcomas (cASs) that responded differently to anlotinib. And genetic analysis revealed that those two sites had different FLT4 variants, suggesting that FLT4 amplification could be the cause of anlotinib non-response.

KEYWORDS cutaneous angiosarcomas, vascular endothelial growth factor receptor (VEGFR), FLT4, anlotinib, soft tissue sarcomas

Introduction

Angiosarcomas (ASs) are rare, aggressive tumors of vascular or lymphatic endothelial cell origin that account for about 2%–3% of all adult soft tissue sarcomas. They can arise from anywhere on the body, with cutaneous angiosarcomas (about 60% of all cases) involving the head and neck, particularly the scalp, followed by the breast, extremity, trunk, liver, and other sites (1, 2). ASs can be divided into primary cutaneous (in the absence of lymphoedema or radiation), parenchymal tissue/visceral (which includes primary breast lesions), deep soft tissue, and lymphoedema-associated and post-radiation angiosarcomas, according to lesion location and underlying risk factors (1, 3). The prognosis of ASs is poor, with approximately 16%–44% of advanced or metastatic patients presenting at the time of diagnosis (2, 4). ASs have a 5-year survival rate of 30%–
40% with overall survival ranging from 6 to 16 months depending on tumor stage, surgical resection, and distant metastases (5, 6).

When compared to Western countries, approximately 50%–60% of cutaneous angiosarcomas (cASs) originate in the head and neck, with Asians involving up to 90% of the scalp and face (7). cASs are more common in elderly men between the ages of 60 and 70 who have distinct clinical causative factors, such as chronically sun-damaged skin or chronic lymphedema/irradiated skin (8). Patients with angiosarcoma of the head and neck have a higher tumor mutation burden and a dominant UV damage mutational signature (9, 10).

Surgical resection with wide excisional margins is the main therapy for R0 resection cASs, but due to insufficient surgical excision and the infiltrative growth pattern, local recurrences or metastases are common, particularly in head and neck locations, with 5-year overall survival of 10%–15% (11, 12). Several studies revealed that age, tumor size, tumor location, resection with positive margins, and advanced stage are the poor prognosis factors for cASs (13–15).

Amplifications of MYC, KLT4, FLT4, and recurrent mutations in TP53, PLCG1 (R707), and PTPRB, as well as genetic alterations in the mitogen-activated protein kinase (MAPK) pathway, have been reported in ASs (9, 16–19). Many antiangiogenic targeted agents, including vascular endothelial growth factor/receptor inhibitors, such as bevacizumab (20), or multi-kinase inhibitors, pazopanib (21, 22), and sunitinib, have demonstrated clinical efficacy in ASs, including cASs, when used alone or in combination with standard therapies. Clinical success with angiogenesis targeting agents, on the other hand, has so far been lacking.

Case description

In December 2018, a 73-year-old male patient discovered on his own a swelling in the left parotid area, initially the size of peanut rice, with local pressure pain but no fever, facial palsy, or taste disturbance. One month later, the swelling had grown to the size of a small date and was diagnosed as a “parotid cyst” at an outside hospital and underwent “left parotid abscess excision.” In March 2019, the patient visited our hospital for a reexamination. The CT scan revealed an irregular mass in the posterior and inferior portion of the left parotid gland, measuring 3.7 × 3.4 cm. This mass had uneven density, mild to moderate enhancement, uneven edges, a poor boundary with the parotid gland, and local skin thickening. Pathological findings postoperatively showed that vascular endothelial derived cells were responsible for the infection, and the immunohistochemical staining showed that CD31 was diffusely positive and the Ki-67 proliferation index was 50%–60%, whereas CD34 was negative (Figures 1A–C), with
lymphoid and plasma cell infiltration and bleeding. The presence of two lymph nodes surrounding the tissue led to a preliminary diagnosis of poorly differentiated AS.

However, a relapse of the local bump behind the left ear 2 months after the operation. Meanwhile, a lesion appeared on the scalp. The scalp was broken locally, the wound was poorly healed, and the surrounding tissues were eroded. A local biopsy revealed CD31, ERG, and Ki-67 were positive, P53 was partially positive, while CK, CD34, CD117, CEA, and P40 were negative, indicating that this was a metastasis (Figures 1D–F). Given the size of the lesion, the patient’s old age, and physical condition, surgery and chemotherapy were risky treatments, and the patient made an informed decision to decline them. So anlotinib, a multi-targeted tyrosine kinase inhibitor approved as second-line treatment for advanced soft-tissue sarcoma, was recommended after complete informed consent in July 2019. During the treatment, the tumor behind the left ear was quickly relieved until it disappeared (Figures 2A–E), but anlotinib was not effective for scalp metastasis, and the lesions continued to deteriorate until they were uncontrollable (Figures 2F–O). This patient died in May 2020 without a relapse behind the left ear.

There was a significant difference in the response to anlotinib between recurrent parotid lesions and scalp metastases. We sequenced the scalp metastatic and the surgically resected primary tissues by Next Generation Sequencing (NGS). The sequencing results showed that the primary lesions only had the FLT4 p.G1276E mutation. However, in addition to the FLT4 p.G1276E mutation, scalp metastasis also exhibited FLT4 amplification and mutations of FLT1/ARID1A/CHEK2/IRS1 (Table 1).

Identification of genomic alterations to confirm predictive biomarkers for anti-angiogenesis therapy is always on the way. The predictive value of the FLT4 F131S mutation to regorafenib was not ruled out because of its extracellular location and complicated genomic profiles (23). Although a 6-month clinical stable response to pazopanib caught our attention in VEGFR-2 or 3 amplified angiosarcoma (24), we should not ignore the potential responsive mechanism of the VEGFR3 R1070L mutation in the tyrosine kinase domain. In our description, the unique and pure FLT4 G1276E mutation may be a reasonable explanation for this rapid and durable response to anlotinib. The amplification of FLT4 by metastatic lesions may be the reason for the
unresponsiveness after constructional analysis of other gene alterations. Further study is ongoing and warranted.

Conclusion

AS is a rare, highly heterogeneous sarcoma with a variety of clinical characteristics. The prognosis of ASs is poor, with a 5-year survival rate of only 30%–40% from primary diagnosis, but once metastasized, the average survival period is less than 1 year. Based on the stage and the location, radical surgery remains the curative treatment for ASs, and adjuvant radiochemotherapy is mainly used to treat locally advanced or progressive patients (6). Targeted agents, including mono-target antibodies, bevacizumab, or multi-target small molecules in tyrosine kinases, pazopanib, and regorafenib, have shown significant clinical efficacy (25). There are some immunotherapy drugs, and combination strategies are being investigated in various subtypes of soft tissue sarcomas, including ASs (26). Due to the complex correlation between drug efficiency and pathological subtype heterogeneity as well as genetic characteristics, treatment options for ASs remain limited (27).

Anlotinib is a new oral molecular multi-target tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor a (PDGFR-a), c-Kit, and fibroblast growth factor receptor (FGFR) 1–3 and inhibits tumor angiogenesis and tumor cell proliferation. It has been approved as a third-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) (28). Based on a preclinical study, anlotinib showed high selectivity for VEGF family members, especially VEGFR2 and VEGFR3, with IC50 values of 0.2 and 0.7 nmol/L, showing high selectivity and inhibitory potency to sunitinib (29). A phase 2 clinical trial involving 166 patients to evaluate anlotinib in recurrent metastatic soft tissue sarcomas found that the overall 12-week PFS and ORR rates were 68% and 13%, respectively, with easily controllable adverse events (30). More trials are being conducted to investigate the efficacy of anlotinib monotherapy, anlotinib plus immunotherapy, and anlotinib plus chemotherapy in advanced sarcomas, particularly soft tissue sarcomas (31). So far, there have been few reports on the efficacy of anlotinib treatment in ASs, with only a few case reports referring to various lesions in head and neck AS (32) and cardiac AS (33) or combined immunotherapy in metastatic primary splenic AS (34). In the case we present, the patient experienced local recurrence in the ear as well as scalp metastases following surgery. Anlotinib was an option chosen when the patient declined chemotherapy and surgery. However, the two lesions respond differently to treatment, with the lesion behind the ear disappearing quickly and the lesion on the scalp worsening. FLT4 p.G1276E mutation rate doubled, and newly added FLT4 amplification as well as point mutation of FLT1/ARID1A/CHEK2/IRS1, according to genetic alterations from primary and metastatic tissues.

The FLT4 gene encodes VEGFR3 and is involved in lymphatic differentiation. It has been reported that inappropriate genetic abnormalities of VEGFR signaling are critical in the genesis of angiosarcomas (35, 36). FLT4 gene amplification, along with MYC, is present in approximately 25% of secondary angiosarcomas (17). A case report described a 6-month clinically stable response to pazopanib in an angiosarcoma patient with VEGFR-2, VEGFR-3 amplification, and a novel VEGFR3 R1070L mutation (24). Arnaud-Coffin et al. (37) also reported a partial response to pazopanib in an FLT4 amplified angiosarcoma patient, but with a worse PFS of 3.1 months. FLT4 amplification was also reported to be a poor prognostic factor for ASs (38). Several basket trials with FLT4 gene amplification subgroups are also being conducted (NCT02693535, NCT02029001, NCT03297606). The FLT1 gene encodes VEGFR1 and is a member of the VEGFR family. The point mutation c.542G>A was found in FLT1’s Ig-like domain 2, which is a high-affinity ligand-binding region (29). Some studies have found that soluble FLT1 expression is associated with poor clinical outcomes and may be a biomarker of intrinsic resistance to anti-angiogenic therapies that selectively inhibit the VEGFR-2 signaling pathway (39). However, no studies have been conducted to investigate the impact of FLT1 extracellular domain mutations on the efficacy of kinase inhibitor therapy.

### TABLE 1 DNA-NGS detection results of the patient.

| Genes | Primary tumor | Scalp metastasis |
|-------|---------------|------------------|
| FLT4  | p.Gly1276Glu (25.58%) | p.Gly1276Glu (68.23%) |
| FLT4  | FLT1          | p.Gly181Glu (4.86%) |
| ARID1A| FLT1          | p.Gln425* (3.25%) |
| CHEK2 | FLT4          | p.Arg3Trp (3.72%) |
| IRS1  | FLT4          | pThr1103Ala (2.91%) |
| TMB   | 0.8 Mut/Mb    | 4.0 Mut/Mb |
| MSI   | MSS           | MSS             |

muts/Mb, mutations per megabase; NGS, next-generation sequencing; TMB, tumor mutational burden; MSI, microsatellite instability; CN, copy number.
ARID1A encodes BAF250A, which is a member of the SWI/SNF chromatin-remodeling complex. ARID1A is a tumor suppressor, and most mutations seen in cancers are frameshift or nonsense mutations that result in inactivation and reduced expression of ARID1A (40). The overall mutation rate of ARID1A in cancers is about 6%, with clear-cell ovarian cancer (45%) and endometrial cancer (37%) being the most common (41, 42). There is a lot of evidence that ARID1A loss-of-function mutations can activate the PI3K/Akt/mTOR pathway (43, 44) and increase the sensitivity of ARID1A-deficient cells to treatment with the PI3K/AKT inhibitor in gastric cancer cells (45) or cholangiocarcinoma (46). Checkpoint kinase 2 (CHEK2) is a cancer susceptibility gene that codes for the serine/threonine CHK2 kinase involved in DNA damage response (DDR). A higher frequency of germline mutations is significantly associated with breast and ovarian cancers (47). Insulin receptor substrate-1 (IRS1) is a mediator of oncogenic IGF signaling and is overexpressed in a variety of malignant tumor types, where it also mediates EGFR or mTOR inhibitor resistance (48–50). Although these mutations are linked to sarcoma development to some extent, there have been no reports of these mutations being linked to sarcoma-targeted therapy resistance.

In our case, FLT4 p.G1276E is a novel mutation localized in the carboxyterminal domain of VEGFR3 that may be the primary reason for the response to anlotinib in the recurrence site, but the FLT4 amplification in the metastatic site may be a worse prognosis factor and showed no response to anlotinib. Our findings may broaden the spectrum of the FLT4 gene mutations while also providing guidance for clinical anlotinib treatment of local recurrence and metastatic ASs.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

YiG treated and observed the patient. YuG, JM, and YiG collected the clinical information, diagnostic information, therapeutic information, and images of the patients. JL performed the histopathological and immunohistochemical examinations. YiG, YuG, JM, and JL prepared the manuscript and the literature search. YJ, XY, and TS performed data analysis and interpretation. YiG and JM reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

Authors YJ, XY, and TS are employed by Jiangsu Simcere Diagnostics Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol (2010) 11(10):983–91. doi: 10.1016/S1470-2045(10)7023-1
2. Singla S, Papavasiliou P, Powers B, Gaughan J, von Mehren M, Watson JC, et al. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg (2014) 208(2):254–9. doi: 10.1016/j.amjsurg.2014.01.007
3. Gaballah AH, Jensen CT, Palmquist S, Pickhardt PJ, Duran A, Broering G, et al. Angiosarcoma: Clinical and imaging features from head to toe. Br J Radiol (2017) 90(1075):20170039. doi: 10.1259/bjr/20170039
4. Buehler D, Rice SR, Moody JS, Rush P, Hafez GR, Attia S, et al. Angiosarcoma. Ann Diagn Pathol (2014) 18(6):254–9. doi: 10.1016/j.anndiagpath.2010.11.002
5. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res (2019) 9(11):2303–13.

6. Boichard A, Wagner MJ, Kurzrock R. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. Genome Med (2020) 12(1):61. doi: 10.1186/s13073-020-00753-2
7. Farid M, Ong WS, Lee MJ, Jeevan R, Ho ZC, Saint AN, et al. Cutaneous versus non-cutaneous angiosarcoma: clinicopathologic features and treatment outcomes in 60 patients at a single Asian cancer centre. Oncology (2013) 85(5):182–90. doi: 10.1159/000354215
8. Ronchi A, Cozzolino I, Zito Marino F, De Chiara A, Argenziano G, Moscarella E, et al. Primary and secondary cutaneous angiosarcoma: Distinctive clinical, pathological and molecular features. Ann Diag Pathol (2020) 48:151597. doi: 10.1016/j.anndiagpath.2020.151597
9. Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The angiosarcoma project: enabling genomic and clinical discoveries in a rare
Pazopanib treatment slows progression and stabilizes disease in patients with angiosarcoma and epithelioid hemangioendothelioma. BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendothelioma of the head and neck: a retrospective monocenter study. J Craniofac Surg (2014) 4(6):376–8. doi: 10.1097/SCS.0000000000000629.

Lee BL, Chen CF, Chen PC, Lee HC, Liao WC, Perig CK, et al. Investigation of prognostic features in primary cutaneous and soft tissue angiosarcoma after surgical resection: A retrospective study. Ann Plast Surg (2017) 78(3 Suppl 2):S41–6. doi: 10.1093/apaees/01001000001004.

Perez MC, Padhye TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, et al. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 20(11):3391–7. doi: 10.1245/s10434-013-3083-6.

Dettendorf T, Wermker K, Schulze HJ, Klein M, Schipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective study. J Craniofac Surg (2014) 4(6):376–8. doi: 10.1097/SCS.0000000000000629.

Lee BL, Chen CF, Chen PC, Lee HC, Liao WC, Perig CK, et al. Investigation of prognostic features in primary cutaneous and soft tissue angiosarcoma after surgical resection: A retrospective study. Ann Plast Surg (2017) 78(3 Suppl 2):S41–6. doi: 10.1093/apaees/01001000001004.

Pazopanib as a potential chemotherapy for cutaneous angiosarcoma: A case series with targeted novel therapeutic approaches. J Dermatol Gastroenterol (2022) 4(4):429–43. doi: 10.1111/ddg.14694.

Manner J, Radlwimmer B, Hohenberger P, Mösinger K, Küffer S, Sauer C, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2010) 176(3):34–9. doi: 10.2353/ajpath.2010.090637.

Cornejo KM, Deng A, Wu H, Cosar EF, Khan A, St Cyr M, et al. The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast. Hum Pathol (2015) 46(6):868–71. doi: 10.1016/j.humpath.2014.02.012.

Goerd LV, Schneider SW, Booken N. Cutaneous angiosarcomas: Molecular pathways and novel therapeutic approaches. J Drugs Dermatol Gastroenterol (2022) (4):376–9. doi: 10.1123/ddg.2021.0029.

Murali R, Scholz SL, Berger M, Huberman K, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2010) 176(3):34–9. doi: 10.2353/ajpath.2010.090637.

Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2010) 176(3):34–9. doi: 10.2353/ajpath.2010.090637.

Antonescu CR, Yoshida A, Gu W, Chang L, Agaran NP, et al. AKT inhibition is an effective therapy for patients with previously treated metastatic colorectal cancer. PLoS One (2012) 7(6):e38231. doi: 10.1371/journal.pone.0038231.

Gu et al. 10.3389/fonc.2022.1027696

Meyerhardt JA, Ancukiewicz M, Abrams-TA, Schrag D, Enzinger PC, Chan JA, et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastatic colorectal cancer. PLoS One (2012) 7(6):e38231. doi: 10.1371/journal.pone.0038231.

Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 46(8):745–50. doi: 10.1002/gcc.20459.

Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A mutations in angiosarcoma: A molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. Am J Surg Pathol (2016) 40(5):645–55. doi: 10.1097/PAS.0000000000000582.

Mullin J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev (2021) 100:102287. doi: 10.1016/j.ctrv.2021.102287.

Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequel of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2003) 22(47):6091–8. doi: 10.1038/sj.onc.1206993.

Yang Y, Wang X, Yang X, Duan J, Wu Z, Yang F, et al. Loss of ARID1A promotes proliferation, migration and invasion via the akt signaling pathway in NPC. Cancer Manag Res (2019) 11:4931–46. doi: 10.2174/16684090196666607329.

Lee D, Yu EL, Ham IB, Hur H, Kim YS. AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells. Onco Targets Ther (2017) 10:4153–9. doi: 10.2147/OTT.S136644.

Tessiri S, Techesan A, Kongphet S, Niaman J, Losolene W, Chan-On W, et al. Therapeutic targeting of ARID1A and PIK3/AKT pathway alterations in cholangiocarcinoma. Peers (2020) 2(7):e12750. doi: 10.7717/peerj.12750.

Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Moaz A, et al. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer (2012) 119(6):2829–36. doi: 10.1111/j.1349-7006.2011.02300.x.

Sun Y, Zhou J, Shi L, Li J, Chen J. MicroRNA–466 inhibits cell proliferation and invasion in osteosarcoma by directly targeting insulin receptor substrate 1. Mol Med Rep (2019) 19(4):3451–52. doi: 10.3892/mmr.2019.9956.

Reuveni H, Flasner-Abramson E, Steiner L, Makedonski K, Song R, Shit A, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 73(14):4383–94. doi: 10.1158/0008-5472.CAN-12-3385.

Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, et al. Preclinical characterization of an insulin receptor substrate 2–inhibitor. Cancer Sci (2018) 109(6):1207–11. doi: 10.1111/cas.13536.